Cardiovascular risk–prediction models in cancer survivors: a meta-analysis
Open Access
- 28 July 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (35) , 4941-4956
Abstract
This systematic review and meta-analysis included 34 studies encompassing 983 438 adult cancer survivors and evaluated the performance of both general-population and cancer-specific cardiovascular risk–prediction models across vascular events, cancer therapy-related cardiac dysfunction or heart failure, arrhythmias, and composite cardiovascular event outcomes. In total, 27 unique risk scores were assessed. Approximately one-third of model–outcome evaluations demonstrated acceptable-to-good discrimination, defined as an area under the curve of ≥0.70. Among general-population models, four risk scores demonstrated acceptable-to-good discrimination for vascular events, three models were acceptable for CTRCD/heart failure, and two models for arrhythmias. The New Zealand CVD score was the only composite outcome model with an AUC ≥0.70. Cancer-specific scores, such as HFA-ICOS and the Ezaz score, showed high specificity for selected outcomes and may support rule-in decisions, although their lower sensitivity limits use for ruling out risk of CTRCD/heart failure. In our subgroup analysis, model performance varied by cancer type, with more consistent discrimination in breast cancer cohorts and substantially poorer performance in survivors of haematologic malignancies, indicating limited transportability across cancer populations. In summary, these findings provide a comprehensive overview of available cardiovascular risk–prediction tools and may assist clinicians in selecting appropriate models for primary cardiovascular prevention in cancer survivors while highlighting the need for exposure-aware, externally validated models tailored to specific cancer populations.Keywords
This publication has 55 references indexed in Scilit:
- Determining the Optimal Sequence of Multiple TestsStatistics in Medicine, 2025
- Developing a simple clinical risk score for ibrutinib-associated atrial fibrillationJournal of Interventional Cardiac Electrophysiology, 2025
- Cardiovascular Toxicity Induced by TKIs in Patients with Chronic Myeloid Leukaemia: Are Women and Men Different?ESC Heart Failure, 2025
- Predicting Cardiovascular Events with Fluoropyrimidine Chemotherapy Using a Standard Cardiovascular Risk CalculatorESC Heart Failure, 2024
- The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibAnnals of Hematology, 2023
- Performance of the pooled cohort equations in cancer survivors: the Atherosclerosis Risk in Communities studyJournal of Cancer Survivorship, 2023
- Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerBreast Cancer Research and Treatment, 2021
- Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomesAnnals of Hematology, 2020
- Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartHematological Oncology, 2019
- Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatmentAnnals of Hematology, 2014